National Health Act 1953 - Amendment determination under paragraph 98C(1)(b) - conditions (No. PB 34 of 2008)

Overview

The National Health Act 1953, enacted by the Commonwealth Parliament, serves as the foundation for the Pharmaceutical Benefits Scheme (PBS) which ensures Australians have access to reliable, timely, and affordable medications. To address the need for up-to-date information on pharmaceutical benefits, the Act allows the Minister for Health to amend the conditions under which payments are made for the supply of these benefits by approved pharmacists and medical practitioners. The Amendment Determination under paragraph 98C(1)(b) of the Act, expressed to commence on 1 April 2008, was made on 3 March 2008, and amends the determination made by legislative instrument number PB 52 of 2007 which came into effect on 1 August 2007. This determination aims to keep the PBS current by adding and deleting specific forms of listed drugs, as recommended by the Pharmaceutical Benefits Advisory Committee, to reflect changes in medical conditions, clinical effectiveness, safety, and cost-effectiveness.

Scope and Application

The National Health Act 1953, as amended by the determination under paragraph 98C(1)(b) and the legislative instrument number PB 34 of 2008, governs the Pharmaceutical Benefits Scheme (PBS) by which the Commonwealth provides Australians with reliable, timely, and affordable access to a range of medicines. The Act applies to pharmaceutical benefits provided by approved pharmacists and medical practitioners, ensuring that these benefits are available under specific conditions. The Minister for Health and Ageing has the authority to declare drugs and medicinal preparations that qualify for the PBS through legislative instruments. These declarations include the form, manner of administration, and brands of pharmaceutical items. The Pharmaceutical Benefits Advisory Committee (PBAC) recommends which drugs and preparations should be available under the PBS, taking into account their clinical effectiveness, safety, and cost-effectiveness. The amendments made by PB 34 of 2008, which came into effect on 1 April 2008, adjust the conditions for payments in respect of the supply of pharmaceutical benefits, including the addition of certain forms of Fentanyl lozenges and Methylphenidate capsules, and the removal of a specific form of Oestradiol nasal spray and Prochlorperazine suppositories from the PBS.

Key Provisions

The National Health Act 1953, through Part VII, forms the legislative foundation for the Pharmaceutical Benefits Scheme (PBS), ensuring Australians have access to affordable and reliable medications. Under section 85(1), the Commonwealth provides benefits for pharmaceuticals, with specific drugs and preparations declared by the Minister as listed drugs under subsection 85(2). The Minister can also determine the form and manner of administration of these drugs through subsections 85(3) and 85(5), and designate a brand for each drug through subsection 85(6). This ensures a clear definition of what constitutes a pharmaceutical benefit under the Act. Additionally, the Minister can determine a responsible person for a brand of a pharmaceutical item under section 84AF. The Act imposes obligations on the Minister and other relevant parties to ensure the smooth operation of the PBS. The Minister must consult with the Pharmaceutical Benefits Advisory Committee (PBAC) before declaring any drug or medicinal preparation as a pharmaceutical benefit under section 100A. The PBAC, an independent expert body established under the Act, provides recommendations based on the clinical effectiveness, safety, and cost-effectiveness of medicines. These recommendations are crucial as a drug or medicinal preparation cannot be declared as a pharmaceutical benefit unless recommended by the PBAC, as stipulated in subsection 101(4). Failure to comply with the conditions set out in the determination under paragraph 98C(1)(b) of the Act can result in various consequences. The amendments under this determination can lead to changes in the forms of drugs available under the PBS, including the addition of new forms like Fentanyl Lozenges and Methylphenidate Capsules, and the removal of others like Oestradiol Nasal Spray and Prochlorperazine Suppositories. While the specific civil or criminal penalties for breaches are not detailed in the text, non-compliance with the PBS regulations can generally result in fines, suspension of benefits, or other legal actions as deemed appropriate by the relevant authorities. The exact penalties would depend on the nature and severity of the breach.